ATOS Stock Price, Analysis & Fundamentals | Atossa Therapeutics, Inc.

Analysis

Atossa Therapeutics, Inc. is a healthcare company operating in the biotechnology industry. With a market capitalization of $79.72 million and 15 employees, the company falls within the small-scale category. The financial health of Atossa Therapeutics indicates significant losses, with net income totaling -$30,180,000 and EBITDA at -$32,840,000 over the trailing twelve months. Gross margin, operating margin, and profit margin are all at 0.0%. Returns on equity and assets are negative, standing at -48.9% and -29.9%, respectively. The company maintains a cash balance of $51.84 million. The valuation of Atossa Therapeutics can be viewed through various metrics, including a forward P/E ratio of -2.15, an EV/EBITDA of -0.90, and a price to book ratio of 1.60.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

Visit website →

ATOS

Price History (1Y)

Analysis

About Atossa Therapeutics, Inc.

Key Statistics

Company Info